Hinge Health Shares Jump 12% on Strong Q2 Earnings and Upgrades

Hinge Health Inc. (NYSE: HNGE) shares surged over 12% in premarket trading on August 6, 2025, reaching $54.40 at 8:06:17 AM EDT, following the release of its Q2 2025 earnings report. The digital health provider significantly outperformed analyst expectations across key financial metrics, sparking analyst upgrades and renewed investor confidence. The stock’s premarket rise reflects strong demand for its musculoskeletal care solutions and growing recognition of the company’s scalable business model.

The company reported second-quarter revenue of $139.1 million, exceeding the $125.4 million consensus estimate by $13.7 million. This marks a 55% year-over-year increase from $89.8 million in Q2 2024, demonstrating Hinge Health’s ability to scale its digital physical therapy platform effectively. The performance was further supported by a 45% year-over-year increase in billings to $196.6 million, with the client base expanding to 2,359—up 39% from 1,785 in the same period last year. The strong financials underscore the company’s growing market penetration and effective sales execution.

Profitability metrics also impressed, with a non-GAAP operating margin of 18.8%, far above the estimated 3.1%. Hinge Health posted non-GAAP earnings per share of $0.33, well above the $0.09 forecast. While the company still reported operational losses, its ability to generate positive non-GAAP income and strong free cash flow indicates progress toward long-term profitability.

Analysts responded positively to the results. Citizens JMP Securities raised its price target for Hinge Health from $58 to $65 and maintained a “Market Outperform” rating. Stifel also increased its price target to $63 from $58, reflecting confidence in the company’s growth trajectory. Raymond James and Needham initiated coverage with “Outperform” and “Buy” ratings, respectively, highlighting Hinge Health’s leadership in virtual musculoskeletal care and its potential for sustained growth. Truist Securities reaffirmed its “Buy” rating with a $48 price target after discussions with company executives.

Looking ahead, Hinge Health provided strong guidance for Q3 2025, projecting revenue between $141 million and $143 million—well above the $129 million estimate. For the full year, the company expects revenue of $548–552 million, surpassing the $511 million forecast. These projections suggest continued momentum as the company expands its platform and introduces new offerings, such as HingeSelect, a provider network expected to launch in 2026.

The stock has performed well since its May 2025 IPO, with shares rising over 63% from the $32 IPO price. This outpaces the Russell 3000 index’s 9% gain over the same period. With a market capitalization of $3.76 billion and a strong financial health score, Hinge Health appears well-positioned to continue its growth in the expanding digital health sector.

While broader market conditions remain mixed, with analysts noting stretched valuations and limited earnings breadth, the healthcare technology sector has shown relative resilience. Hinge Health’s ability to consistently exceed revenue expectations and attract analyst upgrades highlights its strong positioning in a growing market. As investors remain focused on earnings-driven growth, Hinge Health’s Q2 performance reinforces its appeal as a long-term investment.

[1] Tokenist, [https://tokenist.com/why-are-hinge-healthcares-shares-surging-in-premarket-trading-today/](https://tokenist.com/why-are-hinge-healthcares-shares-surging-in-premarket-trading-today/)

[2] TipRanks, [https://www.tipranks.com/news/company-announcements/hinge-health-reports-strong-q2-2025-revenue-growth](https://www.tipranks.com/news/company-announcements/hinge-health-reports-strong-q2-2025-revenue-growth)

[3] Investing.com, [https://www.investing.com/news/analyst-ratings/stifel-raises-hinge-health-stock-price-target-to-63-on-strong-q2-results-93CH-4172766](https://www.investing.com/news/analyst-ratings/stifel-raises-hinge-health-stock-price-target-to-63-on-strong-q2-results-93CH-4172766)

[4] TipRanks, [https://www.tipranks.com/news/the-fly/hinge-health-reports-q2-eps-13-10-vs-96c-last-year-thefly](https://www.tipranks.com/news/the-fly/hinge-health-reports-q2-eps-13-10-vs-96c-last-year-thefly)

[5] AInvest, [https://www.ainvest.com/news/pre-market-volatility-catalyst-driven-stock-swings-unpacking-momentum-pharma-retail-tech-2508/](https://www.ainvest.com/news/pre-market-volatility-catalyst-driven-stock-swings-unpacking-momentum-pharma-retail-tech-2508/)